The reviewed evidence does not establish whether ipamorelin causes water retention, so there is no rate to quote. What exists is FDA's reasoning: ipamorelin raises growth hormone, and fluid retention is a labeled risk of raised growth hormone [1]. Ipamorelin has never been FDA-approved. In October 2024 FDA's compounding advisory committee voted 0 for and 12 against adding it to the 503A list, with 1 abstention [2], and FDA keeps ipamorelin acetate in Category 2 of its 503B list [3].
Not measured, but FDA expects it
The selected published IV studies and FDA review do not establish a reliable rate for chronic subcutaneous use. Failure to report a particular event is not proof of its absence; gastrointestinal distention, joint pain and fluid-related edema are also different outcomes.
FDA filled the gap with a class argument. In its October 2024 review, the agency wrote that it is concerned the risks on approved growth hormone labels, fluid retention among them, will also apply to ipamorelin [1].
Raising growth hormone can make the body hold water
Ipamorelin is a growth hormone secretagogue: it signals the pituitary to release more growth hormone, which raises IGF-1. FDA's briefing lists the warnings carried by every approved recombinant growth hormone label: neoplasm, glucose intolerance and diabetes, raised pressure inside the skull, fluid retention and more [1]. Then it says:
We are concerned that similar potential risks will be associated with the use of ipamorelin (free base) or ipamorelin acetate.[1]
For a picture of what that looks like, the closest approved example is a different drug. Tesamorelin (Egrifta SV) also raises growth hormone, by a different route, and its FDA label describes fluid retention directly:
Fluid retention may occur during EGRIFTA SV therapy and is thought to be related to the induction of GH secretion. This manifests as increased tissue turgor and musculoskeletal discomfort resulting in adverse reactions (e.g. edema, arthralgia, and carpal tunnel syndrome) which are either transient or resolve with discontinuation of treatment.[8]
That label applies to tesamorelin, an approved drug with trial data behind it. It shows the kind of effect FDA has in mind, not a measured ipamorelin rate. How long the effect lasts on tesamorelin is covered in how long tesamorelin stays in your system.
| Question | Ipamorelin | Tesamorelin (Egrifta SV label) |
|---|---|---|
| Measured in studies? | No dependable rate established for repeated subcutaneous use | Yes, label section 5.3 |
| How FDA describes it | A likely class risk of raised growth hormone | Edema, joint pain and carpal tunnel syndrome |
| What happens on stopping | Unknown | Transient, or resolves when treatment stops |
| FDA status | Not approved | Approved for one use |
Sources: FDA PCAC briefing on ipamorelin, October 2024; Egrifta SV label on DailyMed.
Two published IV reports are a selected evidence base
FDA’s 2024 review describes 165 enrolled participants across the two published human studies. In a 1999 dosing study, 48 healthy men got a single 15-minute infusion of ipamorelin or placebo. FDA notes the paper did not state any adverse events [1] [4].
The second was a 2014 phase 2 trial in 117 adults recovering from bowel surgery, with 114 receiving the drug or placebo by vein for up to seven days. It missed its main goal: median time to a tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p = 0.15) [5]. Its safety findings, as FDA summarized them, are below. The postoperative trial analysis explains its endpoint and why its results cannot be transferred to routine wellness use.
| Study | Who | People | Route | What was reported |
|---|---|---|---|---|
| Gobburu 1999 | Healthy men | 48 enrolled | Single IV infusion | No adverse events stated |
| Beck 2014 | Adults after bowel resection | 117 enrolled, 114 treated | IV, up to 7 days | Hyperglycemia at discharge 14.3% vs 8.6%; serious adverse events 17.9% vs 15.5%; 2 deaths on ipamorelin, relation unclear per FDA |
| Helsinn phase 2 (NCT01280344) | Adults after bowel resection | 320 enrolled | Not posted | Primary completion June 2013;overall May 2014;no posted results |
| Repeated injections in healthy adults | No controlled wellness result established here | Not established | Under the skin | FDA case reports are not controlled trials |
Sources: FDA PCAC briefing, October 2024; PubMed; ClinicalTrials.gov.
The deaths need context. Both patients had bowel surgery for colon cancer and then an anastomotic leak, a known surgical complication; the causes included sepsis, hyperkalemia and kidney failure. FDA wrote that it is unclear whether ipamorelin played a part, but that the deaths, with the higher rates of low potassium and high blood sugar, raise safety concerns [1].
The320-person randomized ipamorelin registry reports completion of its primary phase in June 2013 and overall study in May 2014, with no posted results [7]. That distinction matters: it is registered research, but provides no public results to establish benefit, event rates or chronic wellness safety.
Controlled repeated-subcutaneous safety is not established
FDA’s 2024 review did not identify controlled safety or PK data for the proposed subcutaneous products. Its adverse-event section nevertheless describes a two-month subcutaneous ipamorelin-sermorelin exposure with joint pain. A case report demonstrates exposure, not a dependable safety rate [1]. FDA’s current risk page retains uncertainty for other injectable routes [3].
FDA's adverse-event database had two non-serious reports through September 2023. One was joint pain in a man using a compounded injection that combined ipamorelin with sermorelin; the pain eased but did not resolve after he stopped. Because the product held two peptides, FDA said it could not tie the event to ipamorelin [1].
Bloating needs a separate distinction. FDA’s review describes nausea, vomiting and abdominal distention as common gastrointestinal events in the surgical trial, similar in the two treatment groups [1]. That observation is not a measured rate of fluid retention from a subcutaneous peptide regimen. Gastrointestinal distention and fluid-related swelling should not be collapsed into the same outcome.
FDA's other concerns are immune reactions and impurities
Beyond the growth hormone class risks, FDA lists problems specific to compounded ipamorelin [3]:
- Immune reactions, because peptides can clump together or carry impurities, and injection under the skin may strengthen the response.
- Unnatural amino acids in the molecule, which make it harder to confirm what a product contains.
- Glucose intolerance and diabetes, the same class risk that showed up as more high blood sugar in the surgical trial.
- Other growth hormone label risks, including neoplasm and raised pressure inside the skull, which no ipamorelin study was long enough to assess.
These are FDA's stated reasons, not findings from an ipamorelin trial. Ipamorelin's reputation as the "selective" peptide, one that raises growth hormone without raising cortisol, comes from 1998 work in rat cells, rats and pigs, not from people [6]. The combination product many clinics sell is a separate question, covered in is CJC-1295 and ipamorelin safe, and whether the pair works is covered in does CJC-1295 with ipamorelin work.
Swelling on a growth-hormone peptide is worth reporting
If you notice swelling, puffy hands or feet, joint pain, or tingling in your fingers while using any growth-hormone-releasing peptide, tell the prescriber who started it. Those are the effects the tesamorelin label lists for raised growth hormone [8]. Your prescriber can decide what to check and whether to stop.
You can also report it to FDA's MedWatch program. FDA notes that it does not receive every adverse event report, especially for compounded products [1]. For the approved alternative and its full safety label, see is tesamorelin safe. How this site reads FDA documents is explained in how we check.
A current observational registry, NCT07717866, lists 52 actual participants in a multimodal veterans program and names ipamorelin among several physiological-supplementation options. It has no posted results and does not isolate ipamorelin, establish its route-specific safety or test this CJC combination [9].